Japan ticks Gropep mix
Thursday, 21 April, 2005
Adelaide biopharma GroPep has announced that a Japanese biopharmaceutical company has received regulatory approval in Japan to manufacture a biopharmaceutical product containing one of GroPep's products.
GroPep said commercial secrecy prevented it naming the ingredient, the company, or the product, but it is the sixth biopharmaceutical product containing GroPep's proprietary cell-culture products to receive regulatory approval.
It's not going to be a big source of revenue, but GroPep said the Japanese product is currently undergoing clinical trials for several other indications, some of which have multi-billion global markets.
CEO Bob Finder said the Japanese approval reinforced growing international recognition of the superiority of GroPep's cell culture products for the manufacture of certain biopharmaceutical products.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
